HitGen, Inc. Hits Day Low at CNY 27.99 Amid Price Pressure

HitGen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a significant decline today, with its stock price dropping by 9.95%. The stock reached an intraday low of CNY 27.99, reflecting a challenging day in the market. Despite this downturn, HitGen has shown resilience over the longer term, boasting a 38.4% increase over the past year, significantly outperforming the China Shanghai Composite, which recorded a 7.03% gain in the same period. The company's performance metrics indicate a robust financial position, highlighted by a remarkable net profit growth of 114.98% reported in September. HitGen's operating cash flow reached its highest at CNY 204.8 million, and the return on capital employed (ROCE) stood at 8.01%. The company also reported a pre-tax profit of CNY 43.75 million, reflecting a substantial growth of 150.73%. With a market capitalization of CNY 10,782 million and a price-to-earnings ratio of 77.00, HitGen continues to maintain a strong market presence despite today's fluctuations.